Welcome, Guest. Please login or register.
May 27, 2024, 12:35:03 pm

Login with username, password and session length

  • Total Members: 6309
  • Latest: Vicki
  • Total Posts: 55126
  • Total Topics: 4851
  • Online Today: 147
  • Online Ever: 1314
  • (June 22, 2016, 05:23:42 am)
Users Online
Users: 0
Guests: 113
Total: 113


Welcome to the Hep Forums, a round-the-clock discussion area for people who have Fatty Liver Disease, Hepatitis B, C or a co-infection, their friends and family and others with questions about hepatitis and liver health. Check in frequently to read what others have to say, post your comments, and hopefully learn more about how you can reach your own health goals.

Privacy Warning: Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.
  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.
  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.
  • Product advertisement (including links); banners; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from the Hep Forum Moderators.
Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.

Author Topic: FDA Grants Fast-Track Status for NAFLD and NASH Treatments  (Read 9760 times)

0 Members and 1 Guest are viewing this topic.

Offline Hep Forum Moderators

  • Administrator
  • Member
  • Posts: 33
FDA Grants Fast-Track Status for NAFLD and NASH Treatments
« on: March 24, 2016, 09:33:01 am »
The U.S. Food and Drug Administration (FDA) has granted fast-track status to a new program focused on developing premiere treatments for both non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). The initiative, announced by U.S. research company NuSirt Biopharma, hopes to target some of the fastest growing liver diseases in the world, which are commonly associated with obesity, high blood pressure and diabetes.

Currently, both NAFLD and NASH lack any approved treatments in the United States. That’s despite the fact that up to 100 million people across the country are estimated to have NAFLD, and that up to 20 million more have progressed to NASH. Both diseases are the result of fat building up in the liver, which prevents the organ’s ability to remove toxins from the blood. Together, they affect up to one-third of the U.S. population.



© 2024 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.